## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	Responses)																
1. Name and Address of Reporting Person *- NEIS JOHN				2. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [CLRB]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
C/O CELLE AGRICULT		OSCIENCES, IN VE	C 2201	3. Date of 08/20/2		arliest Trar 1	nsaction (1	Month	/Day/Ye	ar)			fficer (give titl	e below)	Other (	specify below	r)
(Street) MADISON, WI 53719				4. If Amendment, Date Original Filed(Month/Day/Year)							_X_ For	6. Individual or Joint/Group Filing(Check Applicable Line) _X. Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City)		(State)	(Zip)			1	able I - N	Non-D	erivativ	e Securi	ties A	cquired, D	isposed of,	or Benefic	ially Owned		
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Yea	2A. Deemed Execution Date, if any (Month/Day/Year)		Date, if	3. Transac Code Instr. 8)	4. Securities Acquires (A) or Disposed of (E) (Instr. 3, 4 and 5)					curities Beneficially g Reported		6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership		
				(		-9)	Code	V	Amou	nt (A)		Price Price		0		(Instr. 4)	
Common St share	tock, par va	alue \$0.00001 per	08/20/2014				P		130,00	00 A	\$ 3.	75 493,7	15		I		See Foonote
Common St share	tock, par va	alue \$0.00001 per	08/20/2014				P(2)		138,71	1 A	\$ 3.	75 632,4	26		I		See Foonote
				(e.g., p		calls, war	s Acquire	d, Dis	ently val sposed of converti	id OME f, or Bei ble secu	3 con neficia	trol numb	er.		n displays a		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Transaction Derivation Securiti Acquire Dispose		e s (A) or	Expiration Date of U (Month/Day/Year) Sec (Ins		of Underly Securities	Title and Amount f Underlying ecurities nstr. 3 and 4)		9. Number of Derivative Securities Beneficially Owned Following	Ownersh Form of Derivativ Security: Direct (D	Ownersh y: (Instr. 4) D)		
				Code	v	(A)	(D)	Date Exerc	cisable	Expirat Date	ion	Title	Amount or Number of Shares		Reported Transaction(s (Instr. 4)	or Indir (I) (Instr. 4	
Stock Purchase Warrant (right to buy)	\$ 4.68	08/20/2014		P		130,000		08/2	0/2014	08/20/	2019	Common Stock	130,000	\$ 0.01	130,000	I	See Foonote
Convertible Debenture (right to buy)	\$ 10	08/20/2014		S(3)			50,000	02/0	6/2014	02/06/	2016	Commor Stock	50,000	\$ 3.75	0	I	See Foonote (1) (2)
Stock Purchase Warrant (right to buy)	\$ 4.68	08/20/2014		P(2)		138,711		08/2	0/2014	08/20/	2019	Commor Stock	138,711	\$ 0.01	268,711	I	See Foonote

### **Reporting Owners**

Donation Openin Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
NEIS JOHN C/O CELLECTAR BIOSCIENCES, INC. 3301 AGRICULTURE DRIVE MADISON, WI 53719	X						

### **Signatures**

/s/ Paul Bork,attorney-in-fact for John Neis	08/22/2014
**Signature of Reporting Person	Date

### **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  - These securities are held by Venture Investors Early Stage Fund IV Limited Partnership and Advantage Capital Wisconsin Partners I, Limited Partnership. VIESF IV GP LLC is the general
- partner of Venture Investors Early Stage Fund IV Limited Partnership and Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of VIESF IV GP LLC and Venture Investors LLC are made collectively by seven managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- (2) These securities were issued in consideration of the tender to the issuer by Venture Investors Early Stage Fund IV Limited Partnership and Advantage Capital Wisconsin Partners I, Limited Partnership of convertible debentures with an aggregate principal amount and accrued interest equal to the purchase price of the securities.
- (3) These securities were tendered to the issuer by Venture Investors Early Stage Fund IV Limited Partnership and Advantage Capital Wisconsin Partners I, Limited Partnership in consideration of the purchase of shares of Common Stock and Stock Purchase awards as described elsewhere in this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.